← Eichor
Study identifier: NCT06972732 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes  ·  Sponsor: Boryung Pharmaceutical Co., Ltd

PhasePhase 4
Planned participants204
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

This description comes directly from the study's public registry record.

Talk to the study team

Oh  ·  +82 2-708-8000  ·  syoh@boryung.co.kr

Always discuss trial participation with your own doctor first.

Locations (1)

The Catholic University of Korea, Seoul St. Mary's HospitalSeoul, Seocho District, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06972732